Journal of neurology, neurosurgery, and psychiatry · 2026
Whole-body quantitative muscle MRI in myotonic dystrophy type 2: a sensitive tool for pattern recognition, disease stratification and objective assessment of clinical severity.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mensch Alexander, Heuschen Maurits Gerhardt Abraham, Barba Lorenzo, Koelsch Anna, Strube David, Kendzierski Thomas, Schneider Ilka, Stapf Caroline Deborah, Kleeberg Kathleen, Kraya Torsten, Kleefeld Felix, Eger Katharina, Sperfeld Anne-Dorte, Troppa Benjamin, Naegel Steffen, Gussew Alexander, Otto Markus, Deistung Andreas, Stoevesandt Dietrich
Аннотация
BACKGROUND: Myotonic dystrophy type 2 (DM2) is a frequent yet underdiagnosed muscle disorder. Although muscle MRI is increasingly used in neuromuscular disorders, there is an overt lack of evidence regarding its role in DM2. This study aimed to characterise whole-body muscle involvement using semiquantitative and quantitative MRI (qMRI) and to determine its relationship with clinical disease severity.
METHODS: In this prospective study, 27 genetically confirmed DM2 patients and 26 age-matched and sex-matched healthy controls underwent whole-body MRI. Semiquantitative muscle involvement was assessed using Fischer grading, while qMRI included fat fraction, T2 and diffusion tensor imaging metrics. Imaging findings were correlated with clinical measures including 6-minute walk test (6MWT), Medical Research Council (MRC) sum score, hip flexion strength, pulmonary function, laboratory parameters and CCTG repeat length.
RESULTS: DM2 patients demonstrated significantly higher muscular degeneration than controls, predominantly involving proximal muscles. Semiquantitative whole-body MRI correlated with MRC sum score, 6MWT and CCTG repeat length. Importantly, the average involvement of the most severely affected muscles closely reflected overall disease burden, indicating that a focused set of muscles adequately captures global muscle involvement. QMRI confirmed these findings, demonstrating increased fat fraction and T2 values, both of which correlated with clinical performance.
CONCLUSIONS: Whole-body qMRI provides a robust, objective biomarker for DM2 severity. The close agreement between focused and whole-body assessment enables efficient disease stratification, with potential applications in clinical trials and personalised patient management. QMRI may provide a standardised imaging outcome measure for future clinical studies in DM2, warranting longitudinal validation.
METHODS: In this prospective study, 27 genetically confirmed DM2 patients and 26 age-matched and sex-matched healthy controls underwent whole-body MRI. Semiquantitative muscle involvement was assessed using Fischer grading, while qMRI included fat fraction, T2 and diffusion tensor imaging metrics. Imaging findings were correlated with clinical measures including 6-minute walk test (6MWT), Medical Research Council (MRC) sum score, hip flexion strength, pulmonary function, laboratory parameters and CCTG repeat length.
RESULTS: DM2 patients demonstrated significantly higher muscular degeneration than controls, predominantly involving proximal muscles. Semiquantitative whole-body MRI correlated with MRC sum score, 6MWT and CCTG repeat length. Importantly, the average involvement of the most severely affected muscles closely reflected overall disease burden, indicating that a focused set of muscles adequately captures global muscle involvement. QMRI confirmed these findings, demonstrating increased fat fraction and T2 values, both of which correlated with clinical performance.
CONCLUSIONS: Whole-body qMRI provides a robust, objective biomarker for DM2 severity. The close agreement between focused and whole-body assessment enables efficient disease stratification, with potential applications in clinical trials and personalised patient management. QMRI may provide a standardised imaging outcome measure for future clinical studies in DM2, warranting longitudinal validation.